Metabolomic biomarkers and metabolic remodelling in genetically characterised hypertrophic cardiomyopathy: a systematic review.

What was studied

This review gathered studies of body chemistry (metabolomics) in hypertrophic cardiomyopathy. All people had known gene changes. It asked which metabolic pathways go off track. It asked if gene variants have their own signs. It also asked if metabolites help diagnosis, outlook or care. 14 studies with 1511 people were found.

What they found

Most studies tested blood plasma or heart tissue. Changes kept showing up in fat, amino acid and ketone pathways. Acyl carnitines, amino acids and eicosanoids were often reported markers. Heart tissue showed poor energy use in cell power plants. No distinct gene-specific signature was found. The pattern followed how severe the disease was, not the causal variant.

What it means for patients

The authors say metabolomics shows potential for better disease description and biomarker discovery. They say longitudinal and externally validated studies are needed before clinical use.

Why it is not certain yet

The abstract does not say how good the studies were. The abstract gives no effect sizes. More longitudinal and externally validated studies are needed. A review can only be as good as the studies in it.

Source

Metabolomic biomarkers and metabolic remodelling in genetically characterised hypertrophic cardiomyopathy: a systematic review.

We restate facts from the source record in our own words. The original wording belongs to its publisher.